Remove 2019 Remove Clinical Trials Remove Presentation Remove Safety
article thumbnail

GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales

Cannabis Law Report

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. 14th at 11:00 a.m. PT (2:00 p.m.

article thumbnail

Study: Oral CBD Use Has Anxiolytic and Anti-Psychotic Activity

The Joint Blog

This is according to a study published in the Journal of Clinical Medicine Research and epublished by the U.S. For the study researchers with the Nordic Cannabis Research Institute in Denmark reviewed 25 clinical trials assessing the safety and efficacy of CBD in various populations. National Institute of Health.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

What is CBN (Cannabinol)? How does the natural byproduct of THC work?

The Cannigma

Therefore, it makes sense that CBN is most commonly found in aged or improperly stored cannabis, and hardly ever present in fresh flower or low-temp extractions. In a 2019 animal study, CBN isolate was reported to relieve musculoskeletal pain. What can the current clinical trials tell us?

THC 140
article thumbnail

Cannabis Helps, Say Over Half of Parkinson’s Patients Who Use It

The Cannigma

In 2019, Parkinson’s UK announced the launch of a major £1.2 million clinical trial investigating the effects of CBD on hallucinations and delusions related to the disease. Still, research is ongoing. The post Cannabis Helps, Say Over Half of Parkinson’s Patients Who Use It appeared first on The Cannigma.

article thumbnail

MAPS Is 36 Years Old – Doblin Provides Precis Timeline of the Organization

Cannabis Law Report

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. MAPS completed the first Phase 1 safety study with MDMA and resumed working on a protocol for anxiety associated with cancer.

article thumbnail

Harvard Law Review: Patents on Psychedelics: The Next Legal Battlefront of Drug Development

Cannabis Law Report

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. The Essay presents proposals to reduce the risk of biopiracy and the issuance of unwarranted psychedelic patents. 12, 2019), [link] [ [link] ]. 10, 2019), [link] [ [link] ]. Mitchell et al.,

article thumbnail

Dentons: Cannabis Group Weekly Alert – August 2019 #3

Cannabis Law Report

Americans for Safe Access released its 2018-2019 State-of-the-State report examining state laws and regulations surrounding Patient Rights and Civil Protection from Discrimination, Access to Medicine, Ease of Navigation, Functionality of the Programs, and Consumer Safety and Provider Requirements. Medical/Health.

Banking 45